QIAGEN N.V. (QGEN) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does QIAGEN N.V. Do?
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. QIAGEN N.V. (QGEN) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Thierry Bernard and employs approximately 6,030 people. With a market capitalization of $8.3B, QGEN is one of the notable companies in the Healthcare sector.
QIAGEN N.V. (QGEN) Stock Rating — Reduce (April 2026)
As of April 2026, QIAGEN N.V. receives a Reduce rating with a composite score of 48.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.QGEN ranks #2,210 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, QIAGEN N.V. ranks #255 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
QGEN Stock Price and 52-Week Range
QIAGEN N.V. (QGEN) currently trades at $40.89. The stock lost $0.12 (0.3%) in the most recent trading session. The 52-week high for QGEN is $57.81, which means the stock is currently trading -29.3% from its annual peak. The 52-week low is $38.13, putting the stock 7.2% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.
Is QGEN Overvalued or Undervalued? — Valuation Analysis
QIAGEN N.V. (QGEN) carries a value factor score of 60/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 107.92x, compared to the Healthcare sector average of 23.63x — a premium of 357%. The price-to-book ratio stands at 2.32x, versus the sector average of 2.75x. The price-to-sales ratio is 1.05x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, QGEN trades at 7.06x EV/EBITDA, versus 6.34x for the sector.
Overall, QGEN's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
QIAGEN N.V. Profitability — ROE, Margins, and Quality Score
QIAGEN N.V. (QGEN) earns a quality factor score of 37/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 9.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 5.9% versus the sector average of -33.1%.
On a margin basis, QIAGEN N.V. reports gross margins of 48.9%, compared to 71.5% for the sector. The operating margin is 4.9% (sector: -66.1%). Net profit margin stands at 4.2%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
QGEN Debt, Balance Sheet, and Financial Health
QIAGEN N.V. has a debt-to-equity ratio of 39.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $1.39B. Cash and equivalents stand at $664M.
QGEN has a beta of 0.50, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for QIAGEN N.V. is 77/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
QIAGEN N.V. Revenue and Earnings History — Quarterly Trend
In TTM 2026, QIAGEN N.V. reported revenue of $1.98B and earnings per share (EPS) of $0.38. Net income for the quarter was $84M. Gross margin was 48.9%. Operating income came in at $98M.
In FY 2024, QIAGEN N.V. reported revenue of $1.98B and earnings per share (EPS) of $0.38. Net income for the quarter was $84M. Gross margin was 48.9%. Revenue grew 0.7% year-over-year compared to FY 2023. Operating income came in at $98M.
In FY 2023, QIAGEN N.V. reported revenue of $1.97B and earnings per share (EPS) of $1.50. Net income for the quarter was $341M. Gross margin was 62.8%. Revenue grew -8.2% year-over-year compared to FY 2022. Operating income came in at $410M.
In FY 2022, QIAGEN N.V. reported revenue of $2.14B and earnings per share (EPS) of $1.86. Net income for the quarter was $423M. Gross margin was 64.6%. Revenue grew -4.9% year-over-year compared to FY 2021. Operating income came in at $531M.
Over the past 8 quarters, QIAGEN N.V. has demonstrated a growth trajectory, with revenue expanding from $1.50B to $1.98B. Investors analyzing QGEN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
QGEN Dividend Yield and Income Analysis
QIAGEN N.V. (QGEN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
QGEN Momentum and Technical Analysis Profile
QIAGEN N.V. (QGEN) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 51/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 26/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
QGEN vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, QIAGEN N.V. (QGEN) ranks #255 out of 838 stocks based on the Blank Capital composite score. This places QGEN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing QGEN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full QGEN vs S&P 500 (SPY) comparison to assess how QIAGEN N.V. stacks up against the broader market across all factor dimensions.
QGEN Next Earnings Date
No upcoming earnings date has been announced for QIAGEN N.V. (QGEN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy QGEN? — Investment Thesis Summary
The quantitative profile for QIAGEN N.V. suggests caution. The quality score of 37/100 flags below-average profitability. The value score of 60/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 77/100) reduces downside risk.
In summary, QIAGEN N.V. (QGEN) earns a Reduce rating with a composite score of 48.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on QGEN stock.
Related Resources for QGEN Investors
Explore more research and tools: QGEN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare QGEN head-to-head with peers: QGEN vs AZN, QGEN vs SLGL, QGEN vs VMD.